Eric Daniel Hamlett

InstitutionMedical University of South Carolina
DepartmentPathology and Laboratory Medicine
AddressP.O. Box MSC 908
Walton Research Building - 39 Sabin Street
ORCID ORCID Icon0000-0002-2900-7949 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Western Carolina University, Cullowhee, NC, USAB.S.06/2002Biological chemistry
    University of North Carolina at Chapel Hill, NC, USAPostbac06/2012Entrepreneurship
    Medical University of South Carolina, Charleston, SC, USAPh.D.05/2017Neurosciences
    University of Denver, Denver, CO, USAPostDoc03/2018Neurosciences
    Collapse awards and honors
    2016SC Aging Research Award, MUSC Center on Aging
    2016Foundation Award, Bright Focus Foundation
    2017 Neuroscience Discovery Award, MilliporeSigma
    2016Innovation Excellence Award, NIH-Center for Advancing Innovation
    2018Ethics in Translational Neuroscience Prize, Herrenhausen Conference
    2018Science Award, Caymen Chemical
    2018Novel Neural Therapies Award, The American Society for Neural Therapy and Repair
    2019Annette Karmiloff-Smith Award, T21 Research Society
    2020Simoa Success Grant Award, Quanterix
    2020 - PresAssociate Editor, Frontiers in Neuroscience

    Collapse Overview 
    Collapse overview
    Dr. Eric D. Hamlett is an Assistant Professor in the Department of Pathology and Laboratory Medicine and the Research Coordinator of the MUSC Carroll A. Campbell, Jr. Neuropathology Laboratory program, which is funded in part by the NIH, NCI, the Down Syndrome International Biobank Program. the Children’s Tumor Foundation, and through various charitable gifts.

    Dr. Hamlett is focused on understanding the mechanisms underlying the pathogenesis of Alzheimer's disease (AD), on finding novel therapeutic targets, and on promoting healthy aging. Dr. Hamlett serves as an Associate Editor for the Journal of Frontiers in Neuroscience and has served as a repeat reviewer for several journals. He comes from a socioeconomic background that is underrepresented in science and stem fields and is a proponent of maximize inclusiveness of a variety of underrepresented talent in Science and Research. Dr. Hamlett seeks to enhance educational opportunities for all students, especially for those that had fewer training opportunities and/or disadvantageous struggles.

    Dr. Hamlett received his B.S. degree in biology and chemistry from Western Carolina University in 2002. He was a Scientist in the McAllister Heart Institute and later served as the Manager of the UNC Systems Proteomics Research Center. He then attended the Medical University of South Carolina, receiving his Ph.D. in Neurosciences in 2017. Dr. Hamlett’s postdoctoral research was performed at the University Denver Knoebel Institute for Healthy Aging (2017-2018). Prior to his arrival at MUSC, Dr. Hamlett served on the communications team for the T21 research society and won several competitive awards in research innovation and entrepreneurial startup.

    The Hamlett laboratory is focused on determining what molecular abnormalities are responsible for the development of neurodegenerative responses associated with AD and using this information to develop effective new treatments to slow or stop this progressive disease. His lab has found evidence that abnormal shedding of AD pathogenic molecules occurs decades, before the first cognitive symptoms are of AD, are experienced. Based on this evidence, we have developed a novel experimental pipeline in which inappropriate passage of pathogenic molecules results in the development of several aspects of the disease in mice. In contrast to previously developed AD mouse models, this system allows normal mice to readily develop several neuropathological signatures of AD at a very high frequency. This model thus gives us a unique opportunity to establish how pathogenic shedding can drive the development of AD without the introduction of major genetic changes and without promoting extremely aggressive disease phenoytpes at young age. Using this model, his lab aims to identify novel classes of compounds that effectively inhibit the pathogenic spread of AD in vivo.

    To identify additional therapeutic targets in AD, the Hamlet lab is also using NextGen sequencing methods to comprehensively identify genetic and epigenetic abnormalities that are specific to glial cells during different stages of AD progression. These studies are being performed using brain specimens collected from human donors to the Carroll A. Campbell, Jr. Neuropathology Laboratory and in our mouse models of AD. These comprehensive approaches thus continue to identify potential new treatment targets, thereby laying the groundwork for the development of effective new therapies for AD.
    Collapse keywords
    Alzheimer's disease, Down syndrome, Neurodegeneration, Neuropathology, Aging, Clinical studies, Biomarkers, Comorbidity, Animal models, Proteomics

    Collapse ORNG Applications 
    Collapse Faculty Mentoring
    Collapse studies/trials
    Collapse Featured Presentations

    Collapse Research 
    Collapse research activities and funding
    3P50DC000422-31A1S1     (DUBNO, JUDY R)Jul 1, 1997 - Aug 31, 2024
    Experimental and Clinical Studies of Presbyacusis
    Role: Co-Investigator

    R01AG055132     (JOSEPH, JANE E)Sep 30, 2017 - Jun 30, 2022
    Using connectomics to characterize risk for Alzheimer's Disease
    Role: Co-Investigator

    R01HD096501     (YU, JEREMY YONGXIN)Aug 22, 2018 - May 31, 2023
    Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics
    Role: Co-Investigator

    R01AG061566     (GRANHOLM-BENTLEY, ANN-CHARLOTTE ESTHER)Feb 1, 2019 - Nov 30, 2023
    Tau pathology in Down syndrome and Alzheimer's
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Zhenwu L, Fitting S, Robinson C, Benitez A, Min L, Wu Y, Xiaoyu F, Amato D, Ning W, Funderburg N, Wagner A, Mcrae-Clark A, Hamlett E, Jiang W. Chronic cannabis smoking-enriched oral pathobiont drives behavioral changes and increases ß-amyloid protein production in the brain.In peer review stage. 2021.
    2. Dierssen M, Herault Y, Helguera P, Martínez de Lagran M,Vazquez A, Christian B, Carmona Iragui M, Wiseman F, Mobley W, Fisher, Brault V, Esbensen A, Jacola LM, Potier M, Hamlett ED, Abbeduto L, del Hoyo Soriano L, Busciglio J, Iulita F, Crispino J, Malinge S, Barone E, Perluigi M, Costanzo F, Delabar J, Bartesaghi R, Dekker A, De Deyn P, Fortea J, Shaw P, Haydar T, Sherman S, Strydom A, Bhattacharyya A. Building future therapies for DS: The Third International Conference of the T21 Research Society.Mol Syndromology. 2021. Accepted in production. 2021.
    3. Iulutita MF, Granholm A, Carmona-Iragui M, Hamlett ED, Fortea J, Ledreux A. Fluid Biomarkers for Alzheimer’s disease in Down syndrome: Current Status and Novel Trends; Book chapter in The Neurobiology of Aging and Alzheimer Disease in Down Syndrome 1st Edition, 2021. ISBN: 9780128188453. 2021.
    4. Lemoine L, Ledreux A, Mufson EJ, Perez SE, Simic G, Doran E, Lott I, Carroll S, Bharani K, Thomas S, Gilmore A, Hamlett ED, Nordberg A, Granholm AC. Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue. 2020; 1(15):68.
    5. Hamlett ED, Hjorth E, Ledreux A, Gilmore A, Schultzberg M, Granholm AC. RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome. Glia. 2020 07; 68(7):1347-1360. PMID: 31944407.
    6. Hamlett ED, Ledreux A, Gilmore A, Vazey EM, Aston-Jones G, Boger HA, Paredes D, Granholm AE. Inhibitory designer receptors aggravate memory loss in a mouse model of down syndrome. Neurobiol Dis. 2020 02; 134:104616. PMID: 31678403.
    7. Hamlett ED, LaRosa A, Mufson EJ, Fortea J, Ledreux A, Granholm AC. Exosome release and cargo in Down syndrome. Dev Neurobiol. 2019 07; 79(7):639-655. PMID: 31347291.
    8. Watson LS, Hamlett ED, Stone TD, Sims-Robinson C. Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimer's disease. Mol Neurodegener. 2019 06 10; 14(1):22. PMID: 31182115.
    9. Hamlett ED, Ledreux A, Potter H, Chial HJ, Patterson D, Espinosa JM, Bettcher BM, Granholm AC. Exosomal biomarkers in Down syndrome and Alzheimer's disease. Free Radic Biol Med. 2018 01; 114:110-121. PMID: 28882786.
    10. Hamlett ED, Goetzl EJ, Ledreux A, Vasilevko V, Boger HA, LaRosa A, Clark D, Carroll SL, Carmona-Iragui M, Fortea J, Mufson EJ, Sabbagh M, Mohammed AH, Hartley D, Doran E, Lott IT, Granholm AC. Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome. Alzheimers Dement. 2017 May; 13(5):541-549. PMID: 27755974.
    11. Hamlett ED, Boger HA, Ledreux A, Kelley CM, Mufson EJ, Falangola MF, Guilfoyle DN, Nixon RA, Patterson D, Duval N, Granholm AC. Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome. Curr Alzheimer Res. 2016; 13(1):35-52. PMID: 26391050.
    12. Hiller S, DeKroon R, Hamlett ED, Xu L, Osorio C, Robinette J, Winnik W, Simington S, Maeda N, Alzate O, Yi X. Alpha-lipoic acid supplementation protects enzymes from damage by nitrosative and oxidative stress. Biochim Biophys Acta. 2016 Jan; 1860(1 Pt A):36-45. PMID: 26344063.
    13. Fortress AM, Hamlett ED, Vazey EM, Aston-Jones G, Cass WA, Boger HA, Granholm AC. Designer receptors enhance memory in a mouse model of Down syndrome. J Neurosci. 2015 Jan 28; 35(4):1343-53. PMID: 25632113.
    14. Nie X, Hamlett ED, Granholm AC, Hui ES, Helpern JA, Jensen JH, Boger HA, Collins HR, Falangola MF. Evidence of altered age-related brain cytoarchitecture in mouse models of down syndrome: a diffusional kurtosis imaging study. Magn Reson Imaging. 2015 May; 33(4):437-47. PMID: 25527393.
    15. Rubel CE, Schisler JC, Hamlett ED, DeKroon RM, Gautel M, Alzate O, Patterson C. Diggin' on u(biquitin): a novel method for the identification of physiological E3 ubiquitin ligase substrates. Cell Biochem Biophys. 2013 Sep; 67(1):127-38. PMID: 23695782.
    16. Londono C, DeKroon RM, Mocanu M, Booe J, Winnik WM, Swank A, Osorio C, Hamlett ED, Alzate O. Proteomic analysis of mice expressing human ApoE demonstrates no differences in global protein solubility between APOE 3 and APOE 4 young mice. Electrophoresis. 2012 Dec; 33(24):3745-55. PMID: 23161654.
    17. Winnik WM, Dekroon RM, Jeong JS, Mocanu M, Robinette JB, Osorio C, Dicheva NN, Hamlett E, Alzate O. Analysis of proteins using DIGE and MALDI mass spectrometry. Methods Mol Biol. 2012; 854:47-66. PMID: 22311753.
    18. DeKroon RM, Robinette JB, Osorio C, Jeong JS, Hamlett E, Mocanu M, Alzate O. Analysis of protein posttranslational modifications using DIGE-based proteomics. Methods Mol Biol. 2012; 854:129-43. PMID: 22311757.
    19. Duan J, Gherghe C, Liu D, Hamlett E, Srikantha L, Rodgers L, Regan JN, Rojas M, Willis M, Leask A, Majesky M, Deb A. Wnt1/ßcatenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. EMBO J. 2012 Jan 18; 31(2):429-42. PMID: 22085926.
    20. Khatun J, Hamlett E, Giddings MC. Incorporating sequence information into the scoring function: a hidden Markov model for improved peptide identification. Bioinformatics. 2008 Mar 01; 24(5):674-81. PMID: 18187442.
    21. Yang D, Ramkissoon K, Hamlett E, Giddings MC. High-accuracy peptide mass fingerprinting using peak intensity data with machine learning. J Proteome Res. 2008 Jan; 7(1):62-9. PMID: 17914788.
    Hamlett's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (120)
    Co-Authors (7)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors